Nordic Nanovector appoints Reza Safaei as head of medical affairs

Nordic Nanovector has appointed Dr. Reza Safaei, MD as Head of Medical Affairs to lead the development and execution of Nordic Nanovector’s medical affairs strategy for Betalutin.

The company said in its press release on Wednesday that Safaei will be responsible for building a team of field-based Medical Science Liaisons (MSL) with initial focus on the US, developing strong relationships with global experts and partnerships with clinical centres of excellence for non-Hodgkin’s lymphoma (NHL), as well as designing and implementing medical education programmes to raise awareness of Nordic Nanovector’s technology and Betalutin prior to launch.

Prior to this Dr. Safaei held the position of Head of Medical Affairs Europe at Seattle Genetics, where he managed medical affairs and clinical development activities of pipeline products in acute myeloid leukaemia and diffuse large B cell lymphoma (DLBCL), bladder cancer and advanced breast cancer.